Tela Bio, INC 10-Q quarterly reports

TELA Bio, Inc. announced its third-quarter 2025 results, reporting a 9% revenue increase to $20.7 million and a 17% reduction in net loss, alongside a new $70 million credit facility and a $13 million direct offering.

TELA Bio, Inc. announced significant revenue growth and a narrower net loss for the second quarter of 2025, driven by new customer additions and product launches, despite continued overall losses.

TELA Bio's first quarter 2025 revenue increased by 12% year-over-year, but the company's net loss also significantly increased due to various factors including the absence of a gain from the sale of a product line that occurred in the prior year.

TELA Bio's Q3 2024 results show a 26% increase in revenue year-over-year, alongside a reduced net loss and the implementation of cost-cutting measures.

TELA Bio's Q2 2024 results show a revenue increase driven by higher unit sales, alongside a strategic sale of a product line, impacting overall profitability.

TELA Bio's first quarter 2024 results show a significant revenue increase of 39% year-over-year, driven by higher unit sales of both OviTex and OviTex PRS products.